Robert W. Duggan Increases Stake in Pulse Biosciences to 71.9% via ATM Offering

On May 13, 2026, Robert W. Duggan filed Amendment No. 17 to his Schedule 13D for Pulse Biosciences, Inc. (PLSE), reporting an increased ownership position. As of the event date on May 11, 2026, Mr. Duggan beneficially owns 49,706,423 shares of common stock, representing approximately 71.9% of the company. This total includes 256,078 shares underlying exercisable options, as well as shares held through controlled entities: 630,109 shares via Genius 24C Inc. and 450,189 shares via Blazon Corporation. The reporting person recently acquired 660,233 shares through the company's at-the-market (ATM) equity offering program at a price of $19.69 per share. The aggregate purchase cost for Mr. Duggan's total holdings is approximately $414.7 million, primarily funded through personal capital. Mr. Duggan continues to serve on the issuer's board of directors and maintains sole voting and dispositive power over his reported shares. The filing also notes he disclaims beneficial ownership of shares held by his spouse, Dr. Maky Zanganeh.